NanoLogix Inc (NNLX)

[globalist]

The test provides a method for rapid, highly specific and sensitive detection and quantification of a virus by observing viral substrate binding to its host receptor protein. It also provides a method for rapid, highly specific and sensitive detection and quantification of a virus in an individual suspected of being infected with a virus. The technology further provides a test kit for rapid, highly specific and sensitive point-of-care detection of a virus in an individual. The surprisingly rapid, specific and sensitive method of the invention provides a point-of care test capable of diagnosing individuals suffering from COVID-19 by observation of a color change in the assay, in about five minutes. The full lab version of the test can be completed by a user in just under one hour, while the home-user abbreviated version is projected to deliver results in about 30 minutes.

While the initial focus for development was for the COVID-19 virus, it became obvious that the technology is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is “Without Limitation”.

The surprisingly rapid, specific and sensitive method of the invention provides a point-of care test capable of diagnosing individuals suffering from COVID-19 by observation of a color change in the assay, in about five minutes.


5 minutes!